# US 2024/0189294 A1 · Method for regulating sebaceous gland

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0189294 A1
- Document ID: US20240189294A1
- Status: Published application
- Kind: A1
- Application number: 18/411,048
- Filed: 2024-01-12
- Published: 2024-06-13
- Earliest claimed: 2021-07-12
- Assignees: Chin-Lon Lin; Buddhist Tzu Chi Medical Foundation
- Applicants: Buddhist Tzu Chi Medical Foundation
- Inventors: Chung-Hsing CHANG
- Web page: https://patentgrep.com/patent/US20240189294A1

## CPC

- A61K 31/4439: containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole (nicotine A61K31/465)
- A61K 9/0014: {Skin, i.e. galenical aspects of topical compositions (non-active ingredients are additionally classified in A61K47/00; A61K9/0009, A61K9/0021, A61K9/7015, A61K9/7023 take precedence; cosmetic preparations A61K8/00, A61Q; preparations for wound dressings or bandages A61L26/00)}
- A61K 31/404: Indoles, e.g. pindolol
- A61K 31/472: Non-condensed isoquinolines, e.g. papaverine
- A61K 31/506: not condensed and containing further heterocyclic rings
- A61P 17/08: Antiseborrheics
- A61P 17/14: for baldness or alopecia
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

A method for regulating sebaceous gland on an area of skin in a subject in need thereof is provided, which includes topically administering to the subject a casein kinase 1 inhibitor. The method can also treat the subject suffering from sebaceous gland-related disorder and/or hair loss. Accordingly, the present disclosure can bring about the effects on increasing hair growth and regulating sebaceous gland in the subject.

## Claims

### Claim 1

A method for regulating sebaceous gland on an area of skin in a subject in need thereof, comprising topically administering to the subject a casein kinase 1 inhibitor.

### Claim 2 (depends on 1)

The method of claim 1, wherein the casein kinase 1 is selected from the group consisting of D4476, IC261, CK17, a compound represented by following general formula I, a compound of following formula II, a compound of following formula III, a compound of following formula IV, a compound of following formula V, and a compound of following formula VI:
wherein:
R1 and R2 are each independently selected from the group consisting of H, straight or branched C1-C8 alkyl, straight or branched C1-C5 alkoxy, straight or branched C1-C5 acyl, C5-C15 aryl, and C3-C7 heteroaryl each optionally substituted by at least one of halide, hydroxyl, ester, ether, C5-C15 aryl, C3-C7 heteroaryl, and amide; or R1 and R2 together with the nitrogen atom they are connected to form a 4 to 7 membered saturated, unsaturated or aromatic ring optionally including at least one of N, O, NH, C═N, C═O and SO2 and optionally substituted with at least one of straight or branched C1-C5 alkyl, C5-C15 aryl, C3-C7 heteroaryl, hydroxyl, halide and cyano;
R3 and R4 are each independently selected from the group consisting of H, straight or branched C1-C8 alkyl optionally substituted by at least one of halide, hydroxyl, alkoxy, C5-C15 aryl, C3-C7 heteroaryl, ester and amide; or
R1 or R2 together with R3 and the carbon and nitrogen atom they are each connected to form a 4 to 7 membered saturated, unsaturated or aromatic ring optionally including at least one of N, NH, O, C═N, C═O, and SO2, and optionally substituted with at least one of straight or branched C1-C5 alkyl, C5-C15 aryl, C3-C7 heteroaryl, hydroxyl, carbonyl, and halide;
R5 and R8 are each independently selected from the group consisting of H, halide, straight or branched C1-C8 alkyl, straight or branched C2-C8 alkenyl, and straight or branched C2-C8 alkynyl optionally substituted by at least one halide;
R6 is selected from straight or branched C1-C8 alkyl, straight or branched C2-C8 alkenyl, straight or branched C2-C8 alkynyl, C5-C10 cycloalkyl, and saturated or unsaturated 4 to 6 membered heterocycle optionally substituted by at least one of straight or branched C1-C8 alkyl, C3-C7 cycloalkyl, 4 to 6 membered heterocycle, C5-C15 aryl, C3-C7 heteroaryl, halide, hydroxyl, and C1-C5 alkyl halide;
R7 is selected from the group consisting of straight or branched C1-C8 alkyl, straight or branched C2-C8 alkenyl, and straight or branched C2-C8 alkynyl optionally substituted by at least one of C3-C7 cycloalkyl, 4 to 6 membered heterocycle, C5-C15 aryl, C3-C7 heteroaryl, halide, hydroxyl, and C1-C5 alkyl halide;

### Claim 3 (depends on 1)

The method of claim 1, wherein the subject suffers from a sebaceous gland-related disorder.

### Claim 4 (depends on 3)

The method of claim 3, wherein the sebaceous gland-related disorder is a sebaceous gland dysfunction and/or a sebum overproduction-related disorder.

### Claim 5 (depends on 4)

The method of claim 4, wherein the sebum overproduction-related disorder is induced by drug, infection, or hormones.

### Claim 6 (depends on 4)

The method of claim 4, wherein the sebum overproduction-related disorder is selected from the group consisting of an acne, a seborrhea, a dermatitis, and an oily skin.

### Claim 7 (depends on 6)

The method of claim 6, wherein the acne is a hormone-induced acne.

### Claim 8 (depends on 6)

The method of claim 6, wherein the dermatitis is an infection-induced dermatitis or a seborrheic dermatitis.

### Claim 9 (depends on 1)

The method of claim 1, wherein the subject suffers from a hair loss.

### Claim 10 (depends on 9)

The method of claim 9, wherein the hair loss is a hair loss caused by nutritional deficiency, a drug-induced hair loss, a radiation-induced hair loss, a stress-induced hair loss, a genetic hair loss, an aging hair loss, or a disease-induced hair loss.

### Claim 11 (depends on 10)

The method of claim 10, wherein the drug-induced hair loss is induced by a chemotherapy drug, lithium, arsenic, bismuth, boric acid, thallium, colchicine, retinoid, heparin, warfarin, β-blocker, an angiotensin-converting enzyme (ACE) inhibitor, a hormone, valproic acid, carbamazepine, phenytoin, cimetidine, an antithyroid drug, a cholesterol-lowering drug, interferon, an anti-infective agent, amphetamine, an antidepressant, an anti-fungal agent, an anti-seizure agent, a birth control agent, a vitamin A-based medication, a medication for Parkinson's disease, a medication for stomach or a nonsteroidal anti-inflammatory drug.

### Claim 12 (depends on 11)

The method of claim 11, wherein the disease-induced hair loss is caused by an autoimmune disease, a thyroid disorder, a metabolic syndrome, an infection, or a cancer.

### Claim 13 (depends on 12)

The method of claim 12, wherein the autoimmune disease is alopecia areata, lupus erythematosus, Sicca syndrome, scleroderma, Crohn's disease, inflammatory bowel disease, or psoriasis.

### Claim 14 (depends on 9)

The method of claim 9, wherein the subject suffers from alopecia.

### Claim 15 (depends on 14)

The method of claim 14, wherein the alopecia is selected from the group consisting of androgenetic alopecia, alopecia areata, anagen effluvium, self-induced hair loss, telogen effluvium, and scarring alopecia.

### Claim 16 (depends on 1)

The method of claim 1, wherein the casein kinase 1 is casein kinase 1a.
